Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
NBIX: third_quarter 2026 lobbying report
IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues
Public: Oct 20, 2026, 3:14 PM EDTOriginal source ↗NBIX: third_quarter 2026 lobbying report
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Public: Oct 20, 2026, 2:20 PM EDTOriginal source ↗NBIX: third_quarter 2026 lobbying report
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432
Public: Oct 20, 2026, 12:10 PM EDTOriginal source ↗NBIX: third_quarter 2026 lobbying report
Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impactin
Public: Oct 18, 2026, 1:41 PM EDTOriginal source ↗NBIX: second_quarter 2026 lobbying report
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Public: Jul 20, 2026, 2:27 PM EDTOriginal source ↗NBIX: second_quarter 2026 lobbying report
IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues
Public: Jul 20, 2026, 2:16 PM EDTOriginal source ↗NBIX: second_quarter 2026 lobbying report
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432
Public: Jul 20, 2026, 12:39 PM EDTOriginal source ↗NBIX: second_quarter 2026 lobbying report
Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impactin
Public: Jul 8, 2026, 3:17 PM EDTOriginal source ↗
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:16 PM EST
- USAspending
- Collection in progress72 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- Federal Register
- Collection in progress298 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable32 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST